MC
MDGL icon

Miles Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Miles Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,654
Closed -$365K – 114
2013
Q3 		$365K Buy
+1,654
New +$352K 0.21% 85

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Miles Capital's MDGL Position: Q4 2013 in Review

Miles Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2013, closing a stake of 1,654 shares — an estimated $365K sold.

Miles Capital first reported a position in MDGL in Q3 2013 and held it in 1 quarter. The position peaked at $365K in Q3 2013. 77 funds tracked by Wall St. Rank hold MDGL as of Q4 2013.

  • Miles Capital reported no remaining Madrigal Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Miles Capital sold 1,654 Madrigal Pharmaceuticals shares in Q4 2013, an estimated $365K.
  • Miles Capital first reported a position in Madrigal Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Miles Capital's Madrigal Pharmaceuticals position peaked at $365K in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2013.

Based on Miles Capital's 13F filing for Q4 2013, filed 11 Feb 2014.